BackImmunoPrecise Antibodies Overview

ImmunoPrecise Antibodies Total Liabilities

Track ImmunoPrecise Antibodies's total liabilities ($8.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$8.19M
↓ 59.87% YoYΔ $-12.22M vs prior year quarter

Peer trimmed avg / median

Loading

ImmunoPrecise Antibodies Total Liabilities History

Loading

ImmunoPrecise Antibodies vs. peers: Total Liabilities Comparison

Loading

ImmunoPrecise Antibodies Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImmunoPrecise Antibodies (IPA) FAQ

As of the most recent data (January 2026), IPA shows a total liabilities of $8.2M. That compares with $20M in the prior-year period — down 59.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPA's total liabilities is now $8.2M (was $20M) — a 59.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ImmunoPrecise Antibodies is outperforming or lagging.

Tracking IPA's total liabilities over time shows whether ImmunoPrecise Antibodies is scaling, shrinking, or reshaping that part of the business. The current reading is $8.2M That compares with $20M in the prior-year period — down 59.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has ImmunoPrecise Antibodies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $8.2M) with ownership activity and broader fundamentals.

ImmunoPrecise Antibodies's total liabilities is $8.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.